Episode Details
Back to Episodes
Sotera Health Beats Q1 Forecasts, Guidance Reaffirmed
Description
Sotera Healths Q1 results exceeded expectations, with revenue of $280 million, a 10% year-over-year increase, and adjusted EBITDA of $134.7 million, a 2.5% rise. Strong performances from Sterigenics and Nordion segments, along with improved Cobalt-60 harvest timing and pricing power, drove growth. Organic revenue grew 6.5%, and operating margins jumped to 27.1%. Despite weather disruptions and softer volumes at Nelson Labs, shares held steady. Management reaffirmed full-year guidance and emphasized key watches for capacity expansion, customer onboarding, regulatory clarity, margin gains, and Nelson Labs volume recovery.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/e8fe39dc686b2f58